Shares of rare-disease specialist Vertex Pharmaceuticals (NASDAQ: VRTX) fell by as much as 15.7% in pre-market trading Thursday morning. The biotech's stock is under pressure today due to a worrying safety signal observed in a midstage trial for the small-molecule drug VX-814 as a potential treatment for alpha-1 antitrypsin deficiency (AATD).
Specifically, the drug's development is reportedly being discontinued after several patients in the study exhibited elevated liver enzymes. AATD is a genetically based condition associated with an increased risk of lung and liver disease.
Image source: Getty Images.
If this double-digit drop in pre-market trading holds, Vertex will lose approximately $10 billion in market capitalization today. While VX-814 stood to be a decent revenue generator for the company, the truth is that this drug would have likely faced stiff competition as an AATD treatment.
Biotechs like Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Dicerna Pharmaceuticals are developing rival AATD therapies, after all. Vertex's sharp pullback today, in turn, seems to be more about shareholders' concerns about the company's non-cystic fibrosis assets -- a market where it sports a virtual monopoly -- than it is about this rare clinical setback.
Vertex isn't throwing in the towel on AATD, however. The biotech announced in the same press release that its other midstage candidate, VX-864, remains on track to produce top-line data sometime in the first half of 2021. What's important to understand is that VX-864 is structurally distinct from VX-814 -- meaning that this clinical failure shouldn't be taken as a preview of things to come for VX-864.
10 stocks we like better than Vertex Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 24, 2020
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.